This white paper examines the evolving biosimilar landscape across 23 European markets and its impact on healthcare costs, patient access, and pharmaceutical competition. IQVIA highlights how biosimilars continue to generate savings, expand access to biologic therapies, and create capacity for investment in innovative medicines while noting emerging challenges such as a slowing pipeline, market maturity, access disparities, and reduced commercial attractiveness. Using key performance indicators across multiple therapeutic areas, the report analyzes trends in pricing, uptake, market share, and competition. It recommends strengthening long-term policy support, improving market incentives, reducing access inequalities, and planning proactively to sustain a competitive biosimilar ecosystem tha

Join for free to read